Lower Risk Myelodysplastic Syndromes (MDS) Market - 2024-2031

August 2024 | 68 pages | ID: LEAA21F1F1EDEN
DataM Intelligence

Abstracts

Lower Risk Myelodysplastic Syndromes (MDS) Market reached US$ 3,362.85 million in 2023 and is expected to reach US$ 7,052.79 million by 2031, growing with a CAGR of 9.70% during the forecast period 2026-2031.

The Lower Risk Myelodysplastic Syndromes (MDS) Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Lower Risk Myelodysplastic Syndromes (MDS) Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Type

• Erythropoiesis-Stimulating Agents (ESAs)*
• Epoetin Alfa
• Darbepoetin Alfa
• Red Blood Cell Transfusion
• Erythroid Maturation Agents
• Demethylating Agents
• Azacitidine
• Decitabine
• Immunosuppressive Agents
• Antithymocyte Globulin
• Cyclosporine
• Others
• Immunomodulatory Agents (Lenalidomide)
• Telomerase Inhibitors
• Others

By Route of Administration

• Oral*
• Parenteral
• Subcutaneous
• Intravenous
• Others

By Age Group

• Adults*
• Geriatrics

By Distribution Channel

• Hospital pharmacies*
• Specialty Pharmacies

Regional Analysis for Lower Risk Myelodysplastic Syndromes (MDS) Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Lower Risk Myelodysplastic Syndromes (MDS) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Treatment Type
3.2. Snippet by Route of Administration
3.3. Snippet by Age Group
3.4. Snippet by Distribution Channel

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Rising product development activities and approval of novel therapies
    4.1.1.2. Rising prevalence of low-risk myelodysplastic syndromes
  4.1.2. Restraints
    4.1.2.1. High cost of treatment
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. BY TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Erythropoiesis-Stimulating Agents (ESAs)*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  6.2.3. Epoetin Alfa
  6.2.4. Darbepoetin Alfa
6.3. Red Blood Cell Transfusion
6.4. Erythroid Maturation Agents
6.5. Demethylating Agents
  6.5.1. Azacitidine
  6.5.2. Decitabine
6.6. Immunosuppressive Agents
  6.6.1. Antithymocyte Globulin
  6.6.2. Cyclosporine
  6.6.3. Others
6.7. Immunomodulatory Agents (Lenalidomide)
6.8. Telomerase Inhibitors
6.9. Others

7. BY ROUTE OF ADMINISTRATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
  7.3.1. Subcutaneous
  7.3.2. Intravenous
  7.3.3. Others

8. BY AGE GROUP

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  8.1.2. Market Attractiveness Index, By Age Group
8.2. Adults*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Geriatrics

9. BY DISTRIBUTION CHANNEL

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital pharmacies*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Pharmacies

10. BY REGION

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  10.1.2. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.2.7.1. The U.S.
    10.2.7.2. Canada
    10.2.7.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    10.3.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.3.6.2. Germany
    10.3.6.3. UK
    10.3.6.4. France
    10.3.6.5. Italy
    10.3.6.6. Spain
    10.3.6.7. Rest of Europe
10.4. South America
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    10.4.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.4.6.2. Brazil
    10.4.6.3. Argentina
    10.4.6.4. Rest of South America
10.5. Asia-Pacific
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    10.5.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.5.6.2. China
    10.5.6.3. India
    10.5.6.4. Japan
    10.5.6.5. South Korea
    10.5.6.6. Rest of Asia-Pacific
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. COMPANY PROFILES

12.1. Johnson & Johnson Services, Inc.*
  12.1.1. Company Overview
  12.1.2. Product Portfolio and Description
  12.1.3. Financial Overview
  12.1.4. Key Developments
12.2. Amgen Inc.
12.3. Bristol-Myers Squibb Company
12.4. Pfizer Inc.
12.5. Sanofi-Aventis U.S. LLC.
12.6. AbbVie Inc.
12.7. Novartis AG
12.8. Otsuka Pharmaceutical Co., Ltd
12.9. Geron.
12.10. Keros Therapeutics (*LIST NOT EXHAUSTIVE)

13. APPENDIX

13.1. About Us and Services
13.2. Contact Us